XML 62 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segments of Business and Geographic Areas (Tables)
 12 Months Ended
Dec. 29, 2019
Segment Reporting [Abstract]  
Schedule of Sales by Segment of Business

 
 
Sales to Customers
 
% Change
(Dollars in Millions)
 
2019
 
2018
 
2017
 
’19 vs. ’18
 
’18 vs. ’17
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
362

 
422

 
449

 
(14.2
)%
 
(6.0
)
     International
 
1,313

 
1,436

 
1,467

 
(8.6
)
 
(2.1
)
     Worldwide
 
1,675

 
1,858

 
1,916

 
(9.9
)
 
(3.0
)
Beauty
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,392

 
2,403

 
2,335

 
(0.4
)
 
2.9

     International
 
2,201

 
1,979

 
1,865

 
11.2

 
6.1

     Worldwide
 
4,593

 
4,382

 
4,200

 
4.8

 
4.3

Oral Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
621

 
637

 
616

 
(2.5
)
 
3.4

     International
 
906

 
918

 
915

 
(1.2
)
 
0.3

     Worldwide
 
1,528

 
1,555

 
1,531

 
(1.7
)
 
1.6

OTC
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,010

 
1,850

 
1,716

 
8.6

 
7.8

     International
 
2,434

 
2,484

 
2,410

 
(2.0
)
 
3.1

     Worldwide
 
4,444

 
4,334

 
4,126

 
2.5

 
5.0

Women's Health
 
 
 
 
 
 
 
 
 
 
     U.S.
 
12

 
13

 
12

 
(5.5
)
 
8.3

     International
 
974

 
1,036

 
1,038

 
(6.0
)
 
(0.2
)
     Worldwide
 
986

 
1,049

 
1,050

 
(6.0
)
 
(0.1
)
Wound Care/Other
 
 
 
 
 
 
 
 
 
 
     U.S.
 
441

 
436

 
437

 
1.2

 
(0.2
)
     International
 
230

 
239

 
342

 
(3.9
)
 
(30.1
)
     Worldwide
 
671

 
675

 
779

 
(0.6
)
 
(13.4
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,839

 
5,761

 
5,565

 
1.4

 
3.5

     International
 
8,059

 
8,092

 
8,037

 
(0.4
)
 
0.7

     Worldwide
 
13,898

 
13,853

 
13,602

 
0.3

 
1.8

 
 
 
 
 
 
 
 
 
 
 
PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
     U.S.
 
9,641

 
9,073

 
8,871

 
6.3

 
2.3

     International
 
4,309

 
4,047

 
3,373

 
6.5

 
20.0

     Worldwide
 
13,950

 
13,120

 
12,244

 
6.3

 
7.2

     REMICADE®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,079

 
3,664

 
4,525

 
(16.0
)
 
(19.0
)
     U.S. Exports
 
294

 
436

 
563

 
(32.7
)
 
(22.6
)
     International
 
1,007

 
1,226

 
1,227

 
(17.8
)
 
(0.1
)
     Worldwide
 
4,380

 
5,326

 
6,315

 
(17.8
)
 
(15.7
)
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,159

 
1,051

 
954

 
10.2

 
10.2

     International
 
1,029

 
1,033

 
879

 
(0.4
)
 
17.5

     Worldwide
 
2,188

 
2,084

 
1,833

 
5.0

 
13.7

     STELARA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4,346

 
3,469

 
2,767

 
25.3

 
25.4

     International
 
2,015

 
1,687

 
1,244

 
19.4

 
35.6

     Worldwide
 
6,361

 
5,156

 
4,011

 
23.4

 
28.5

     TREMFYA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
764

 
453

 
62

 
68.5

 
*
     International
 
248

 
91

 
1

 
*
 
*
     Worldwide
 
1,012

 
544

 
63

 
85.9

 
*
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—
     International
 
10

 
10

 
22

 
4.5

 
(54.5
)
     Worldwide
 
10

 
10

 
22

 
4.5

 
(54.5
)
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,597

 
1,378

 
1,358

 
15.9

 
1.5

     International
 
1,815

 
1,926

 
1,796

 
(5.7
)
 
7.2

     Worldwide
 
3,413

 
3,304

 
3,154

 
3.3

 
4.8

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
     U.S.
 
50

 
58

 
58

 
(13.7
)
 
0.0

     International
 
812

 
758

 
656

 
7.1

 
15.5

     Worldwide
 
861

 
816

 
714

 
5.6

 
14.3

     PREZISTA® / PREZCOBIX® /                                                REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,422

 
1,169

 
1,109

 
21.6

 
5.4

     International
 
689

 
786

 
712

 
(12.3
)
 
10.4

     Worldwide
 
2,110

 
1,955

 
1,821

 
8.0

 
7.4

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
126

 
151

 
191

 
(16.5
)
 
(20.9
)
     International
 
315

 
382

 
428

 
(17.6
)
 
(10.7
)
     Worldwide
 
441

 
533

 
619

 
(17.3
)
 
(13.9
)
 
 
 
 
 
 
 
 
 
 
 
Neuroscience
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,919

 
2,574

 
2,630

 
13.4

 
(2.1
)
     International
 
3,409

 
3,503

 
3,356

 
(2.7
)
 
4.4

     Worldwide
 
6,328

 
6,077

 
5,986

 
4.1

 
1.5

     CONCERTA® / Methylphenidate
 
 
 
 
 
 
 
 
 
 
     U.S.
 
233

 
229

 
384

 
1.7

 
(40.4
)
     International
 
463

 
434

 
407

 
6.6

 
6.6

     Worldwide
 
696

 
663

 
791

 
4.9

 
(16.2
)
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,107

 
1,791

 
1,590

 
17.6

 
12.6

     International
 
1,224

 
1,137

 
979

 
7.7

 
16.1

     Worldwide
 
3,330

 
2,928

 
2,569

 
13.7

 
14.0

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
314

 
315

 
360

 
(0.3
)
 
(12.5
)
     International
 
374

 
422

 
445

 
(11.4
)
 
(5.2
)
     Worldwide
 
688

 
737

 
805

 
(6.7
)
 
(8.4
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
     U.S.
 
266

 
239

 
296

 
11.4

 
(19.3
)
     International
 
1,349

 
1,510

 
1,525

 
(10.7
)
 
(1.0
)
     Worldwide
 
1,614

 
1,749

 
1,821

 
(7.7
)
 
(4.0
)
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
     U.S.
 
4,299

 
4,331

 
3,098

 
(0.7
)
 
39.8

     International
 
6,393

 
5,513

 
4,160

 
16.0

 
32.5

     Worldwide
 
10,692

 
9,844

 
7,258

 
8.6

 
35.6

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,567

 
1,203

 
884

 
30.3

 
36.1

     International
 
1,430

 
822

 
358

 
73.9

 
*
     Worldwide
 
2,998

 
2,025

 
1,242

 
48.0

 
63.0

     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,555

 
1,129

 
841

 
37.7

 
34.2

     International
 
1,856

 
1,486

 
1,052

 
24.9

 
41.3

     Worldwide
 
3,411

 
2,615

 
1,893

 
30.4

 
38.1

     VELCADE®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—

 
—

     International
 
751

 
1,116

 
1,114

 
(32.7
)
 
0.2

     Worldwide
 
751

 
1,116

 
1,114

 
(32.7
)
 
0.2

     ZYTIGA® /abiraterone acetate
 
 
 
 
 
 
 
 
 
 
     U.S.
 
810

 
1,771

 
1,228

 
(54.3
)
 
44.2

     International
 
1,985

 
1,727

 
1,277

 
15.0

 
35.2

     Worldwide
 
2,795

 
3,498

 
2,505

 
(20.1
)
 
39.6

     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
367

 
228

 
145

 
61.0

 
57.2

     International
 
371

 
362

 
359

 
2.4

 
0.8

     Worldwide
 
739

 
590

 
504

 
25.0

 
17.1

 
 
 
 
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,684

 
1,651

 
773

 
2.0

 
*
     International
 
939

 
922

 
554

 
1.9

 
66.4

     Worldwide
 
2,623

 
2,573

 
1,327

 
1.9

 
93.9

     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
766

 
700

 
320

 
9.4

 
*
     International
 
562

 
515

 
253

 
9.0

 
*
     Worldwide
 
1,327

 
1,215

 
573

 
9.2

 
*
     TRACLEER® / bosentan
 
 
 
 
 
 
 
 
 
 
     U.S.
 
131

 
268

 
161

 
(51.1
)
 
66.5

     International
 
210

 
278

 
242

 
(24.3
)
 
14.9

     Worldwide
 
341

 
546

 
403

 
(37.5
)
 
35.5

     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
714

 
598

 
238

 
19.3

 
*
     International
 
105

 
65

 
25

 
62.4

 
*
     Worldwide
 
819

 
663

 
263

 
23.5

 
*
     OTHER 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
74

 
85

 
54

 
(13.7
)
 
57.4

     International
 
62

 
64

 
34

 
(3.7
)
 
88.2

     Worldwide
 
135

 
149

 
88

 
(9.4
)
 
69.3

Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,734

 
4,279

 
4,744

 
(12.7
)
 
(9.8
)
     International
 
1,458

 
1,537

 
1,543

 
(5.2
)
 
(0.4
)
     Worldwide
 
5,192

 
5,816

 
6,287

 
(10.7
)
 
(7.5
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,313

 
2,477

 
2,500

 
(6.6
)
 
(0.9
)
     International
 
—

 
—

 
—

 
—

 
—

     Worldwide
 
2,313

 
2,477

 
2,500

 
(6.6
)
 
(0.9
)
     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
536

 
711

 
944

 
(24.6
)
 
(24.7
)
     International
 
199

 
170

 
167

 
17.3

 
1.8

     Worldwide
 
735

 
881

 
1,111

 
(16.5
)
 
(20.7
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
     U.S.
 
505

 
674

 
675

 
(25.1
)
 
(0.1
)
     International
 
285

 
314

 
297

 
(9.2
)
 
5.7

     Worldwide
 
790

 
988

 
972

 
(20.0
)
 
1.6

     OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
380

 
417

 
625

 
(9.1
)
 
(33.3
)
     International
 
974

 
1,053

 
1,079

 
(7.6
)
 
(2.4
)
     Worldwide
 
1,353

 
1,470

 
1,704

 
(8.0
)
 
(13.7
)
 
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
23,874

 
23,286

 
21,474

 
2.5

 
8.4

     International
 
18,324

 
17,448

 
14,782

 
5.0

 
18.0

     Worldwide
 
42,198

 
40,734

 
36,256

 
3.6

 
12.4

 
 
 
 
 
 
 
 
 
 
 
MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
371

 
612

 
*
 
(39.4
)
     International
 
—

 
638

 
1,003

 
*
 
(36.4
)
     Worldwide
 
—

 
1,009

 
1,615

 
*
 
(37.5
)
Diagnostics
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—

 
—
 
—

     International
 
—

 
—

 
1

 
—
 
*
     Worldwide
 
—

 
—

 
1

 
—
 
*
Interventional Solutions
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,443

 
1,283

 
1,148

 
12.5

 
11.8

     International
 
1,554

 
1,363

 
1,148

 
14.0

 
18.7

     Worldwide
 
2,997

 
2,646

 
2,296

 
13.3

 
15.2

Orthopaedics
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,319

 
5,281

 
5,404

 
0.7

 
(2.3
)
     International
 
3,520

 
3,604

 
3,654

 
(2.3
)
 
(1.4
)
     Worldwide
 
8,839

 
8,885

 
9,058

 
(0.5
)
 
(1.9
)
     HIPS
 
 
 
 
 
 
 
 
 
 
     U.S.
 
863

 
841

 
827

 
2.6

 
1.7

     International
 
575

 
577

 
567

 
(0.3
)
 
1.8

     Worldwide
 
1,438

 
1,418

 
1,394

 
1.4

 
1.7

     KNEES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
889

 
911

 
948

 
(2.4
)
 
(3.9
)
     International
 
591

 
591

 
575

 
0.0

 
2.8

     Worldwide
 
1,480

 
1,502

 
1,523

 
(1.4
)
 
(1.4
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,652

 
1,599

 
1,576

 
3.3

 
1.5

     International
 
1,068

 
1,100

 
1,040

 
(2.9
)
 
5.8

     Worldwide
 
2,720

 
2,699

 
2,616

 
0.8

 
3.2

     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,915

 
1,930

 
2,053

 
(0.8
)
 
(6.0
)
     International
 
1,286

 
1,336

 
1,472

 
(3.8
)
 
(9.2
)
     Worldwide
 
3,201

 
3,266

 
3,525

 
(2.0
)
 
(7.3
)
Surgery
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,828

 
4,125

 
4,085

 
(7.2
)
 
1.0

     International
 
5,673

 
5,776

 
5,474

 
(1.8
)
 
5.5

     Worldwide
 
9,501

 
9,901

 
9,559

 
(4.0
)
 
3.6

     ADVANCED
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,637

 
1,657

 
1,620

 
(1.2
)
 
2.3

     International
 
2,458

 
2,345

 
2,136

 
4.8

 
9.8

     Worldwide
 
4,095

 
4,002

 
3,756

 
2.3

 
6.5

     GENERAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,762

 
1,751

 
1,728

 
0.6

 
1.3

     International
 
2,718

 
2,806

 
2,735

 
(3.1
)
 
2.6

     Worldwide
 
4,480

 
4,557

 
4,463

 
(1.7
)
 
2.1

     SPECIALTY
 
 
 
 
 
 
 
 
 
 
     U.S.
 
430

 
717

 
737

 
(40.1
)
 
(2.7
)
     International
 
497

 
625

 
603

 
(20.5
)
 
3.6

     Worldwide
 
926

 
1,342

 
1,340

 
(31.0
)
 
0.1

Vision
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,794

 
1,777

 
1,575

 
0.9

 
12.8

     International
 
2,830

 
2,776

 
2,488

 
2.0

 
11.6

     Worldwide
 
4,624

 
4,553

 
4,063

 
1.6

 
12.1

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,304

 
1,237

 
1,122

 
5.4

 
10.2

     International
 
2,088

 
2,065

 
1,914

 
1.1

 
7.9

     Worldwide
 
3,392

 
3,302

 
3,036

 
2.7

 
8.8

     SURGICAL
 
 
 
 
 
 
 
 
 
 
     U.S.
 
490

 
540

 
453

 
(9.4
)
 
19.2

     International
 
742

 
711

 
574

 
4.4

 
23.9

     Worldwide
 
1,232

 
1,251

 
1,027

 
(1.6
)
 
21.8

 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
     U.S.
 
12,384

 
12,837

 
12,824

 
(3.5
)
 
0.1

     International
 
13,579

 
14,157

 
13,768

 
(4.1
)
 
2.8

     Worldwide
 
25,963

 
26,994

 
26,592

 
(3.8
)
 
1.5

 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
     U.S.
 
42,097

 
41,884

 
39,863

 
0.5

 
5.1

     International
 
39,962

 
39,697

 
36,587

 
0.7

 
8.5

     Worldwide
 
$
82,059

 
81,581

 
76,450

 
0.6
 %
 
6.7

*Percentage greater than 100% or not meaningful
Schedule of Segment Reporting Information
 
 
Income Before Tax
 
Identifiable Assets
(Dollars in Millions)
 
2019 (3)
 
2018 (4)
 
2017 (5)
 
2019
 
2018
Consumer
 
$
2,061

 
2,320

 
2,524

 
$
26,618

 
25,877

Pharmaceutical
 
8,816

 
12,568

 
11,083

 
56,292

 
56,636

Medical Devices
 
7,286

 
4,397

 
5,392

 
49,462

 
46,254

Total
 
18,163

 
19,285

 
18,999

 
132,372

 
128,767

Less: Expense not allocated to segments (1)
 
835

 
1,286

 
1,326

 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
25,356

 
24,187

Worldwide total
 
$
17,328

 
17,999

 
17,673

 
$
157,728

 
152,954


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2019
 
2018
 
2017
 
2019
 
2018
 
2017
Consumer
 
$
328

 
438

 
485

 
$
765

 
688

 
674

Pharmaceutical
 
950

 
1,012

 
936

 
3,910

 
3,802

 
2,416

Medical Devices
 
1,912

 
1,843

 
1,566

 
2,014

 
2,103

 
2,216

Segments total
 
3,190

 
3,293

 
2,987

 
6,689

 
6,593

 
5,306

General corporate
 
308

 
377

 
292

 
320

 
336

 
336

Worldwide total
 
$
3,498

 
3,670

 
3,279

 
$
7,009

 
6,929

 
5,642
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2019
 
2018
 
2017
 
2019
 
2018
United States
 
$
42,097

 
41,884

 
39,863

 
$
41,528

 
37,117

Europe
 
18,466

 
18,753

 
17,126

 
48,015

 
51,433

Western Hemisphere excluding U.S. 
 
5,941

 
6,113

 
6,041

 
2,862

 
2,752

Asia-Pacific, Africa
 
15,555

 
14,831

 
13,420

 
5,486

 
2,733

Segments total
 
82,059

 
81,581

 
76,450

 
97,891

 
94,035

General corporate
 
 
 
 
 
 
 
1,049

 
1,064

Other non long-lived assets
 
 
 
 
 
 
 
58,788

 
57,855

Worldwide total
 
$
82,059

 
81,581

 
76,450

 
$
157,728

 
152,954

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2019, the Company utilized three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues.

(1) 
Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2) 
General corporate includes cash, cash equivalents and marketable securities.
(3) 
The Consumer segment includes a gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO, litigation expense of $0.4 billion and a restructuring charge of $0.1 billion. The Pharmaceutical segment includes litigation expense of $4.3 billion including $4.0 billion related to the agreement in principle to settle opioid litigation (see Note 21 to the Consolidated Financial Statements for additional information regarding the opioid litigation), an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, an unrealized gain on securities of $0.6 billion, Actelion acquisition related costs of $0.2 billion and a restructuring charge of $0.1 billion. The Medical Devices segment includes a gain of $2.0 billion from the divestiture of the ASP business, a restructuring related charge of $0.4 billion, litigation expense of $0.4 billion and Auris Health acquisition related costs of $0.1 billion.
(4) 
The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL® and litigation expense of $0.3 billion. The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion, Actelion acquisition related costs of $0.2 billion, unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion, a restructuring related charge of $0.6 billion, AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business.
(5) 
The Pharmaceutical segment includes $0.8 billion for Actelion acquisition and integration related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion. The Medical Devices segment includes litigation expense of $1.1 billion, a restructuring related charge of $0.8 billion, an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED®.
(6) 
Long-lived assets include property, plant and equipment, net for 2019, and 2018 of $17,658 and $17,035, respectively, and intangible assets and goodwill, net for 2019 and 2018 of $81,282 and $78,064, respectively.